vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $133.7M, roughly 1.4× FIRST COMMONWEALTH FINANCIAL CORP). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs -0.7%, a 28.8% gap on every dollar of revenue. On growth, FIRST COMMONWEALTH FINANCIAL CORP posted the faster year-over-year revenue change (13.0% vs 0.7%). Over the past eight quarters, FIRST COMMONWEALTH FINANCIAL CORP's revenue compounded faster (5.5% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
AVNS vs FCF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $133.7M |
| Net Profit | $-1.3M | $37.5M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 28.1% |
| Revenue YoY | 0.7% | 13.0% |
| Net Profit YoY | 99.7% | 14.8% |
| EPS (diluted) | $-0.02 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $133.7M | ||
| Q4 25 | $180.9M | $137.9M | ||
| Q3 25 | $177.8M | $136.0M | ||
| Q2 25 | $175.0M | $131.0M | ||
| Q1 25 | $167.5M | $118.0M | ||
| Q4 24 | $179.6M | $120.4M | ||
| Q3 24 | $170.4M | $121.2M | ||
| Q2 24 | $171.7M | $120.2M |
| Q1 26 | — | $37.5M | ||
| Q4 25 | $-1.3M | $44.9M | ||
| Q3 25 | $-1.4M | $41.3M | ||
| Q2 25 | $-76.8M | $33.4M | ||
| Q1 25 | $6.6M | $32.7M | ||
| Q4 24 | $-397.3M | $35.8M | ||
| Q3 24 | $4.3M | $32.1M | ||
| Q2 24 | $1.8M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 40.9% | ||
| Q3 25 | 0.1% | 38.1% | ||
| Q2 25 | -42.6% | 32.1% | ||
| Q1 25 | 6.1% | 34.8% | ||
| Q4 24 | -233.0% | 37.1% | ||
| Q3 24 | 7.0% | 33.4% | ||
| Q2 24 | 3.7% | 38.7% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | -0.7% | 32.5% | ||
| Q3 25 | -0.8% | 30.4% | ||
| Q2 25 | -43.9% | 25.5% | ||
| Q1 25 | 3.9% | 27.7% | ||
| Q4 24 | -221.2% | 29.8% | ||
| Q3 24 | 2.5% | 26.5% | ||
| Q2 24 | 1.0% | 30.9% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $-0.02 | $0.44 | ||
| Q3 25 | $-0.03 | $0.39 | ||
| Q2 25 | $-1.66 | $0.32 | ||
| Q1 25 | $0.14 | $0.32 | ||
| Q4 24 | $-8.64 | $0.35 | ||
| Q3 24 | $0.09 | $0.31 | ||
| Q2 24 | $0.04 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $154.9M |
| Stockholders' EquityBook value | $778.2M | $1.6B |
| Total Assets | $1.1B | $12.3B |
| Debt / EquityLower = less leverage | 0.12× | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — |
| Q1 26 | — | $154.9M | ||
| Q4 25 | $90.3M | $261.7M | ||
| Q3 25 | $93.4M | $262.1M | ||
| Q2 25 | $95.7M | $262.4M | ||
| Q1 25 | $98.0M | $262.7M | ||
| Q4 24 | $125.3M | $263.0M | ||
| Q3 24 | $152.6M | $136.3M | ||
| Q2 24 | $164.9M | $136.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $778.2M | $1.6B | ||
| Q3 25 | $778.0M | $1.5B | ||
| Q2 25 | $776.3M | $1.5B | ||
| Q1 25 | $839.4M | $1.4B | ||
| Q4 24 | $828.5M | $1.4B | ||
| Q3 24 | $1.2B | $1.4B | ||
| Q2 24 | $1.2B | $1.4B |
| Q1 26 | — | $12.3B | ||
| Q4 25 | $1.1B | $12.3B | ||
| Q3 25 | $1.1B | $12.3B | ||
| Q2 25 | $1.0B | $12.2B | ||
| Q1 25 | $1.1B | $11.8B | ||
| Q4 24 | $1.2B | $11.6B | ||
| Q3 24 | $1.7B | $12.0B | ||
| Q2 24 | $1.7B | $11.6B |
| Q1 26 | — | 0.10× | ||
| Q4 25 | 0.12× | 0.17× | ||
| Q3 25 | 0.12× | 0.17× | ||
| Q2 25 | 0.12× | 0.17× | ||
| Q1 25 | 0.12× | 0.18× | ||
| Q4 24 | 0.15× | 0.19× | ||
| Q3 24 | 0.12× | 0.10× | ||
| Q2 24 | 0.13× | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $187.5M | ||
| Q3 25 | $14.0M | $49.5M | ||
| Q2 25 | $6.8M | $30.4M | ||
| Q1 25 | $25.7M | $55.9M | ||
| Q4 24 | $57.9M | $129.5M | ||
| Q3 24 | $23.0M | $53.6M | ||
| Q2 24 | $27.8M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $171.5M | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $113.9M | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 124.3% | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | 94.6% | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 11.7% | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | 12.9% | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.18× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | 3.89× | 1.71× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | 5.35× | 1.67× | ||
| Q2 24 | 15.44× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FCF
Segment breakdown not available.
